XML 67 R57.htm IDEA: XBRL DOCUMENT
v3.24.3

Significant agreements - Summary of Contract Assets and Liabilities (Details) - USD ($) | 9 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2024 | Dec. 31, 2023
Contract liabilities: |  |
Beginning Balance | $ 135,194,000 | $ 61,873,000
Additions | 328,000 | 95,960,000
Deductions | (31,567,000) | (26,976,000)
Impact of Exchange Rates | 5,236,000 | 4,337,000
Ending Balance | 109,191,000 | 135,194,000
Contract assets |  |
Contract assets | 0 | 0
Bayer collaboration deferred revenue |  |
Contract liabilities: |  |
Beginning Balance | 43,618,000 | 0
Additions | 238,000 | 45,000,000
Deductions | (2,496,000) | (1,160,000)
Impact of Exchange Rates | 2,155,000 | (222,000)
Ending Balance | 43,515,000 | 43,618,000
Bayer collaboration deferred revenue | Deferred revenue material rights option |  |
Contract liabilities: |  |
Ending Balance | 34,100,000 |
Novartis collaboration deferred revenue |  |
Contract liabilities: |  |
Beginning Balance | 50,008,000 | 0
Additions | 0 | 50,000,000
Deductions | (6,301,000) | (1,909,000)
Impact of Exchange Rates | 2,264,000 | 1,917,000
Ending Balance | 45,971,000 | 50,008,000
Novartis collaboration deferred revenue | Deferred revenue material rights option |  |
Contract liabilities: |  |
Ending Balance | 32,300,000 |
Ionis collaboration deferred revenue |  |
Contract liabilities: |  |
Beginning Balance | 12,464,000 | 21,489,000
Additions | 90,000 | 960,000
Deductions | (8,881,000) | (10,734,000)
Impact of Exchange Rates | 128,000 | 749,000
Ending Balance | 3,801,000 | 12,464,000
Ionis collaboration deferred revenue | Deferred revenue material rights option |  |
Contract liabilities: |  |
Ending Balance | 3,800,000 |
Genentech collaboration deferred revenue |  |
Contract liabilities: |  |
Beginning Balance | 29,104,000 | 39,308,000
Additions | 0 | 0
Deductions | (13,889,000) | (11,969,000)
Impact of Exchange Rates | 689,000 | 1,765,000
Ending Balance | 15,904,000 | 29,104,000
Genentech collaboration deferred revenue | Deferred revenue material rights option |  |
Contract liabilities: |  |
Ending Balance | 14,400,000 |
AstraZeneca collaboration deferred revenue |  |
Contract liabilities: |  |
Beginning Balance | $ 0 | 1,076,000
Additions |  | 0
Deductions |  | (1,204,000)
Impact of Exchange Rates |  | 128,000
Ending Balance |  | $ 0

X
- Definition Amount of increase in contract with customer, liability. + References No definition available. + Details
Name: | bcyc_ContractWithCustomerLiabilityAdditions
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of decrease in contract with customer, liability. + References No definition available. + Details
Name: | bcyc_ContractWithCustomerLiabilityDeductions
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of adjustment in contract with customer, liability due to change in foreign exchange. + References No definition available. + Details
Name: | bcyc_ContractWithCustomerLiabilityForeignCurrencyAdjustment
Namespace Prefix: | bcyc_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ChangeInContractWithCustomerAssetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ChangeInContractWithCustomerLiabilityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerAssetNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_BayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bcyc_DeferredRevenueMaterialRightsOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_NovartisCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_IonisCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bcyc_AstrazenecaCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |